TRADEMARK

Nizoral

(ketoconazole) tablets

over 5 million prescriptions world-wide.

Oral medication in antifungal therapy:



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but often problematic fungal infections can now be treated effectively *and elegantly.*

Typically, in *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.

JANSSEN PHARMACEUTICA

the drug discovery company

Prescribing information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I.-tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H_2-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynaecomastia has been reported.



MST™

Morphine Sulphate B.P. Continus® Tablets

SOONER RATHER THAN LATER

For full prescribing information see overleaf.

AUGMENTIN

clavulanate-potentiated amoxycillin

A MAJOR DEVELOPMENT IN ANTIBIOTIC THERAPY



In recent years, the treatment of infection has been complicated by the increasing prevalence of ß-lactamase producing strains of bacteria. ß-lactamase destroys many oral cephalosporins and penicillins,[1,2] resulting in treatment failure.

AUGMENTIN is the first antibiotic to utilise Beecham's discovery of the powerful ß-lactamase inhibitor, clavulanic acid. This neutralises the bacterial defence, bringing more strains and species within the scope of oral therapy.

- **AUGMENTIN – Broader in spectrum** than oral cephalosporins, co-trimoxazole, ampicillin, tetracycline or erythromycin.
- **AUGMENTIN – Outstanding success** against today's infections.

Adult infections	No. of patients assessed	Clinically cured/ improved	Clinical success
Upper respiratory tract[3]	146	141	**97%**
Lower respiratory tract[3]	98	89	**91%**
Urinary tract[3]	175	167	**95%**
Skin & soft tissue[3,4]	81	75	**93%**

Paediatric infections	No. of patients assessed	Clinically cured/ improved	Clinical success
Upper respiratory tract[5,6]	70	70	**100%**
Lower respiratory tract[7]	28	27	**96%**
Urinary tract[6,7,8]	61	57	**93%**

PRESCRIBING INFORMATION

INDICATIONS: Chest, ear, nose, throat, genito-urinary, skin and soft tissue infections including those caused by ß-lactamase producing organisms.
DOSAGE: Adults and children over 12 years one AUGMENTIN tablet (375mg) three times daily. **Children 7-12 years** 10ml AUGMENTIN syrup (312mg) three times daily. **Children 2-7 years** 5ml AUGMENTIN syrup (156mg) three times daily. **Children 9 months – 2 years** 2.5ml AUGMENTIN syrup (78mg) three times daily. In severe infections these dosages may be doubled. Treatment should not be extended beyond 14 days without review.
CONTRA-INDICATION: Penicillin hypersensitivity. **PRECAUTIONS:** Safety in human pregnancy is yet to be established. Oral dosage need not be reduced in patients with renal impairment unless dialysis is required. **SIDE-EFFECTS:** Uncommon, mainly mild and transitory, eg diarrhoea, indigestion, nausea, vomiting, candidiasis, urticarial and morbilliform rashes. If gastro-intestinal side-effects do occur they may be reduced by taking AUGMENTIN at the start of meals. **PRESENTATIONS:** 375mg AUGMENTIN tablets each containing 250mg amoxycillin (1) and 125mg Clavulanic acid. (2) 156.25mg AUGMENTIN syrup. Powder for preparing fruit flavoured syrup. When dispensed each 5ml contains 125mg amoxycillin (1) and 31.25mg clavulanic acid. (2) (1) as the trihydrate, (2) as the potassium salt.
Not all presentations are available in every country.

Further information is available from:
Beecham Research Laboratories
Brentford, Middlesex, England.

References 1. Proc. Int. Symp. on AUGMENTIN, Excerpta Med. (1980), **ICS 544**, 173. 2. Excerpta Med. (1980), **ICS 544**, 19. 3. Excerpta Med. (1980), **ICS 544**, 187. 4. Scot. Med. J., (1982), **27**, S35. 5. Proc. Europ. Symp. on AUGMENTIN, Excerpta Med. (1982), **CCP4**, 341. 6. Excerpta Med. (1982), **CCP4**, 347. 7. Excerpta Med. (1982), **CCP4**, 325. 8. Excerpta Med. (1982), **CCP4**, 334.

THE CARDIOPROTECTIVE CORONARY THERAPEUTIC AGENT ADALAT®

THE MODERN COMPREHENSIVE DRUG THERAPY OF CORONARY HEART DISEASE.

Composition: 1 capsule of Adalat contains 10 mg of nifedipine. Indications: 1. Coronary heart disease: Chronic stable angina pectoris, angina at rest, including vasospastic angina pectoris (Prinzmetal's angina, variant angina) and unstable angina (crescendo pre-infarction angina), post-infarction angina (except for the first 8 days following the acute event). 2. Hypertension. Contraindications: Adalat must not be used at any time during pregnancy. No findings are as yet available as regards its use during the nursing period. Caution should be exercised if blood pressure is extremely low (severe hypotension: SBP < 90 mmHg). Cardiovascular shock. Side effects: Adverse reactions occur predominantly at the beginning of treatment and are often mild and transient: facial flush, heat sensation, headache. In isolated cases after high doses: nausea, dizziness, fatigue, skin reactions, paraesthesia, hypotensive reaction, palpitations and rise in pulse rate. Occasionally leg oedemas may occur as a result of vasodilation. Very rare: Gingival hyperplasia may develop during prolonged treatment, however, this is completely reversible after medication has been stopped; chest pain (possibly angina pectoris-like symptoms), in this case nifedipine should be discontinued, if a causal relationship is suspected. Caution must be exercised in patients who have to undergo regular dialysis and suffer from malignant hypertension and in irreversible renal failure associated with hypovolaemia, since blood pressure may fall as a result of vasodilation. Antihypertensive treatment with this drug requires regular medical check-ups. The response to drug intake may in individual cases be such that the ability to drive or operate machinery is impaired. These reactions are especially pronounced at the start of treatment and in the case of a change in medication and, moreover, if alcohol is consumed at the same time. Interactions with other drugs: Nifedipine/antihypertensives: Concomitant use may intensify the blood pressure-lowering effect of nifedipine. Nifedipine/beta-receptor blockers: Concomitant use requires careful monitoring of the patient, since the hypotensive effect may be enhanced; moreover, the development of heart failure has occasionally been reported. Nifedipine/cimetidine: The blood pressure-lowering effect may be intensified. Presentation: Adalat: Packages containing 30, 50 and 100 capsules of 10 mg of nifedipine. Co.-No.: 1a.
Bayer, Germany.

E 6/003

ADALAT

THE CARDIOPROTECTIVE CORONARY THERAPEUTIC AGENT

BAYER



Bayer